<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From 1987 an abrupt increase of the number of patients presented with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> has been registered </plain></SENT>
<SENT sid="1" pm="."><plain>We present our experiences in the treatment of 42 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The number of the male patients was two times larger than of the females </plain></SENT>
<SENT sid="3" pm="."><plain>They were most frequently diagnosed as having RAB (43%) and RAEBt (28.5%) </plain></SENT>
<SENT sid="4" pm="."><plain>RA was found in 14%, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> in 9.5% and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>. in only 5% of the cases </plain></SENT>
<SENT sid="5" pm="."><plain>The treatment was accomplished with ultralow (3 mg/m2/12h s.c.) and low doses (10 mg/m2/12h s.c.) of ARA-C in 75% of the patients with RAEBt and 44.4% with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, while the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> group received <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The treatment improved hematologic results but the complete remission lacked </plain></SENT>
<SENT sid="7" pm="."><plain>In 23.8% of the cases the disease developed into <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Patients excepted from <z:chebi fb="0" ids="35610">cytostatic</z:chebi> therapy were observed by the use of <z:chebi fb="5" ids="50113">androgens</z:chebi>, anabolics, vitamin A+D3 and transfusion of separated erythrocytes </plain></SENT>
<SENT sid="9" pm="."><plain>In 38% of the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> a lethal outcome followed </plain></SENT>
<SENT sid="10" pm="."><plain>Life of those in whom the disease developed into <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> in statistically significatly shorter (p &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>There was no statistically significant difference in the survival rate between the treated and nontreated patients (p &gt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>Further treatment of these patients includes, apart from ultralow doses of ARA-C, the use of <z:chebi fb="2" ids="26536">retinoic acid</z:chebi>, a growth factor (GM-CSF) and bone marrow transplantation </plain></SENT>
</text></document>